Immunology Drug Discovery @JnanaTx | previously CRI Fellow @Harvardmed in the lab of Dr. Arlene H. Sharpe & PhD from @EmoryUniversity in @JBossLab
Boston, MA
Joined October 2019
- Tweets369
- Following327
- Followers206
- Likes817
Dillon Patterson retweeted
Today in @Nature we report a new prime editing strategy that can rescue a common cause of many genetic diseases in a disease-agnostic manner. This approach converts a redundant endogenous tRNA into an optimized suppressor tRNA, enabling a single prime edit to rescue premature stop codons across different diseases.
(1/15)
drive.google.com/file/d/1bSv…
Dillon Patterson retweeted
Excited to share our paper in
@NatImmunol! Using in vivo #CRISPR screens we identify the E3 ligase STUB1 as a new cancer immunotherapy target in CD8 T cells. STUB1 is a dual function target: STUB1 KO promotes CD8 responses and STUB1 KO hinders tumor cells. rdcu.be/eAnE2
Dillon Patterson retweeted
Our aging manuscript is finally out in the November issue @CIR_AACR! Check out if you are interested in understanding how aging impact anti-tumor immunity and response to anti-PD1 ICB! #aging #Tcell
Age-Associated Contraction of Tumor-Specific T Cells Impairs Antitumor Immunity. bit.ly/4fNcVPZ @jameshan_sj
Dillon Patterson retweeted
apply.interfolio.com/155292
Emory Biology @emorycollege is hiring! We invite applications for a tenure track Asst Prof position in the area of epigenetics, including chromatin biology, nuclear organization, cellular differentiation, development, and/or gene regulation. Please share!
Dillon Patterson retweeted
We’re proud to share that Jnana is now part of Otsuka Pharmaceutical Co. and will operate as a direct subsidiary in Boston. We look forward to continuing our R&D efforts and advancing JNT-517 into a Ph 3 pivotal study for #PKU in 2025. bit.ly/3ZD6b2q
#biotech
Dillon Patterson retweeted
Today, we shared positive results from the Ph 1/2 clinical trial of JNT-517 in adults with phenylketonuria (PKU).
Based on these results, we plan to advance JNT-517 directly into a pivotal Ph 3 study in early 2025. More: bit.ly/47fmynI #clinicaltrials #SSIEM #SSIEM2024
Dillon Patterson retweeted
The Greenleaf lab is looking to recruit graduate students and postdocs interested in combinatorial cell state engineering. If you are interested combining multiplex perturbations and single cell readouts to "push" cells into target states, email Will!
Congratulations to the entire Jnana team. Looking forward to working with our new colleagues!
Jnana announced today that it has entered into an agreement to be acquired by Otsuka Pharmaceutical.
bit.ly/4ftndW9 #biotech #news
The supplemental video for Figure 6 with the custom soundtrack absolutely made my Saturday hahaha 😂. Wondering if the fastball didn’t change the loops if a Juan Soto or Aaron Judge swing would…
Congrats to you and your team.
It’s finally out! 🥳 Today @cellcellpress we report non-mineral fossils of ancient chromosomes in skin from a woolly mammoth that died in Siberia, 52,000 years ago.
🦣💨
Don’t miss our thread below! 🧵👇🏽
Amazing paper and thread
Biggest paper yet from the lab out now in @ImmunityCP! It is a massive #openscience resource on #tissueTregs, and what makes #Tregs tick in the #tissues. Spoiler-alert: Tissue Tregs are really different from what we all thought. 🧵 1/21
sciencedirect.com/science/ar…
Awesome ! @Satpathology looking forward to following the progress
Happy to share what we’ve been building at Santa Ana Bio! Immunotherapies that precisely target immune cell types underlying autoimmune disease with a goal of bringing three new antibodies to clinical trials next year. Congratulations to Peter Emtage and the SAB team, and has been so wonderful to partner with close friends and colleagues Sasha Rudensky, @FlavellLab, Graham Lord, Danny Wells, @JerelDavis13, Brendan Bulik-Sullivan, @vintweeta, Shin Fuse
Dillon Patterson retweeted
Happy to share what we’ve been building at Santa Ana Bio! Immunotherapies that precisely target immune cell types underlying autoimmune disease with a goal of bringing three new antibodies to clinical trials next year. Congratulations to Peter Emtage and the SAB team, and has been so wonderful to partner with close friends and colleagues Sasha Rudensky, @FlavellLab, Graham Lord, Danny Wells, @JerelDavis13, Brendan Bulik-Sullivan, @vintweeta, Shin Fuse
Welcome to GV, Santa Ana Bio!
We're thrilled to lead Santa Ana Bio's Series B as the company furthers the development of targeted therapies for patients with autoimmune and inflammatory diseases.
Learn more about today's news in @FierceBiotech — fiercebiotech.com/biotech/in…
Dillon Patterson retweeted
Always fun to see great science from great labs (and great friends). @DebattamaSen nature.com/articles/s41590-0…
Thank you @jnanatx for sending a congratulatory gift for our new addition to our family - Baby Graham! Great place to work for exciting science with amazing talented people!
Dillon Patterson retweeted
Does anyone happen to have or know anyone who has a chst4 cre or cre-ert2 or cdh5 cre-ert2 in the united states that would be willing to share? Please retweet 🙏!!!
Dillon Patterson retweeted
Congratulations to Dr. Gordon Freeman @DanaFarber @harvardmed, who was awarded with the prestigious @AACR- Cancer Research Institute Lloyd J. Old Award in Cancer Immunology at the annual American Association for Cancer Research meeting! Discover: bit.ly/3VNljbG #AACR24
Dillon Patterson retweeted
It’s @rarediseaseday, which raises awareness for the 300 million people living with a rare disease around the world.
Our lead program is a potential 1st-in-class oral treatment for #PKU, a rare inherited metabolic disorder. Learn more: bit.ly/3TcX1WN
#rarediseaseday
Dillon Patterson retweeted
How did we lose our tail? A simple question.. but it wasn't really asked before! We discovered a plausible scenario for the genetic mechanism that led to tail loss. Amazing that such a big change may have been caused by such a small genetic event. nature.com/articles/s41586-0… @BoXia7
Really important paper for in vivo CRISPR screens! Check it out
Excited to share our paper in @JExpMed! We report an experimental and analytical framework for performing in vivo #CRISPR screens in immune cells, using UMIs for improving statistical power and tracking clonal dynamics. hubs.la/Q02mqFV_0
